Yuhan Corporation announced on the 11th that it will receive $60 million (approximately 80 billion KRW) in commercialization royalties for its non-small cell lung cancer treatment "lazertinib"…

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the Phase 2 clinical trial of "NLY01," a new drug candidate being developed by D&D…

Park Jaehyun, CEO of Hanmi Pharmaceutical, retained his position following a board decision that rejected the proposal to appoint Lim Jongyoon, an internal director, as CEO. On August 2, Hanmi…

SK Biopharmaceuticals has set an ambitious goal to emerge as a global player in the radiopharmaceutical(RPT) sector within the next three years. The company plans to strengthen its capabilities…

Celltrion has signed a listing agreement for Zymfentra with the major U.S. insurer Cigna, following its successful agreements with the three largest Pharmacy Benefit Managers (PBMs) just five months…

There is a growing consensus that aesthetic-focused companies, which demonstrated strong stock performance in Q2, will drive growth in the healthcare and medical device industries in the second half…

Voronoi, a drug development specialist that recently licensed out its autoimmune disease treatment pipeline to a U.S. pharmaceutical company, is expected to maintain its competitive edge in the…

"When coincidences accumulate, they become inevitable. The fact that LECLAZA, which I once crossed paths with, came back to me, and the timing of developing LECLAZA and RYBREVANT together—everything…

Celltrion announced on the 12th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 Investigational New Drug (IND) application for 'CT-P51', a biosimilar to…

Daewoong Pharmaceutical achieved its highest-ever quarterly performance in Q2, driven by a focus on new drugs and an increased share of in-house products. On August 9, Daewoong announced that it…